Educational tool · Women's sexual health

FSFI: Female Sexual Function Index and sexual desire (libido) calculator

Answer the 19 questions of the Female Sexual Function Index (FSFI), the most widely used research questionnaire to assess desire, arousal, lubrication, orgasm, satisfaction and pain. The result shows the total score and each domain score, with the published cutoffs.

FSFI Calculator

Female Sexual Function Index · 19 questions · ~5 min

Your answers stay on this device. Nothing is sent or stored.

How to answer: think only about the past 4 weeks and choose the option that best describes your experience. There are no right or wrong answers.

Definitions used in the questionnaire
  • Sexual activity: caressing, foreplay, masturbation and vaginal intercourse.
  • Sexual intercourse: penile penetration (entry) of the vagina.
  • Sexual stimulation: foreplay with a partner, self-stimulation (masturbation) or sexual fantasy.
  • Sexual desire or interest: wanting to have a sexual experience, feeling receptive to a partner's sexual initiation, and thinking or fantasizing about having sex.
  • Sexual arousal: a feeling with both physical and mental aspects — warmth or tingling in the genitals, lubrication (wetness) or muscle contractions.

What the FSFI is

The Female Sexual Function Index (FSFI) was published by Rosen and colleagues in 2000 as a brief, self-report, multidimensional questionnaire to assess female sexual function (Rosen et al., 2000). Its 19 questions cover the past 4 weeks and are grouped into six domains: desire, arousal, lubrication, orgasm, satisfaction and pain.

Since then, the FSFI has become the reference scale in studies on female sexuality and has been validated in women with arousal, orgasm and hypoactive sexual desire disorders (Meston, 2003). It has also been cross-culturally adapted and validated in several languages, including Brazilian Portuguese (Pacagnella et al., 2008; 2009).

In short: the FSFI measures how sexual function has been over the past weeks. It does not measure how much this bothers the person — and that distress is an essential part of any diagnosis of sexual dysfunction.

How the score is calculated

Each answer is worth 0 (or 1) to 5 points. The items of each domain are added and multiplied by the domain factor, so that every domain is on a scale up to 6 points. The total score is the sum of the six domains and ranges from 2 to 36 (Rosen et al., 2000).

DomainQuestionsPoints per itemFactorDomain range
Desire1–21–50.61.2 – 6.0
Arousal3–60–50.30 – 6.0
Lubrication7–100–50.30 – 6.0
Orgasm11–130–50.40 – 6.0
Satisfaction14–160 (or 1)–50.40.8 – 6.0
Pain17–190–50.40 – 6.0
Total score (sum of domains)2.0 – 36.0

An answer of 0 means “no sexual activity” or “did not attempt intercourse” during the period. So someone without sexual activity in those 4 weeks tends to score low even without any difficulty — an important point when interpreting (see Limitations). In the pain domain the scoring is reversed: a higher score means less pain.

How to interpret the result

In every domain, higher scores indicate better sexual function. The cutoffs below come from studies comparing women with and without a clinical diagnosis of sexual dysfunction:

MeasureCutoffWhat it suggestsSource
Total score≤ 26.55🔴 Suggests difficulty in sexual function that deserves evaluationWiegel et al., 2005
Total score> 26.55🟢 Range seen in women without sexual dysfunctionWiegel et al., 2005
Desire domain≤ 5.0🟡 Positive screen for hypoactive sexual desireGerstenberger et al., 2010

The other domains do not have widely validated stand-alone cutoffs. In the calculator they are shown against the 6-point maximum to highlight where the greatest difficulty lies — useful to guide the conversation in a consultation, but not a diagnosis.

Desire domain: the FSFI as a libido scale

The first two FSFI questions measure the frequency and level of sexual desire. Gerstenberger and colleagues analyzed this domain and proposed a cutoff of 5.0 or lower to identify women with probable hypoactive sexual desire disorder (Gerstenberger et al., 2010).

Low desire alone is not a disease. For the International Society for the Study of Women's Sexual Health (ISSWSH), hypoactive sexual desire disorder involves a lack of motivation for sexual activity that causes personal distress and persists for at least several months, not better explained by another condition (Clayton et al., 2018). That is why, when the desire domain is low, a distress scale such as the FSDS-R is often added (Derogatis et al., 2008).

How common is it? In the PRESIDE study, with more than 31,000 women in the United States, about 43% reported some sexual problem, but only about 12% reported associated distress — and the most frequent problem was low desire (Shifren et al., 2008).

What can affect desire and sexual function

The recommended approach is biopsychosocial: several factors usually act together (Clayton et al., 2018). Among the most cited:

On hormones: the 2019 international consensus on testosterone for women concluded that the only evidence-based indication is hypoactive sexual desire disorder with distress in postmenopausal women, after a full clinical evaluation (Davis et al., 2019). There are not yet enough data for other indications, and use without medical follow-up is not recommended.

Limitations of the FSFI

FSFI-6 and other scales

There is a short version, the FSFI-6, with one question per domain, validated for quick screening; a score of 19 or lower suggests sexual dysfunction (Isidori et al., 2010). The full version used in this calculator provides more detail per domain.

ScaleWhat it assessesWhen it is usually used
FSFI (19 items)Six domains of sexual functionDetailed assessment and research
FSFI-6One question per domainQuick screening
FSDS-RDistress related to sexual lifeComplements the FSFI when desire is the complaint

Frequently asked questions

Can the FSFI diagnose sexual dysfunction?

Not on its own. It is a screening and follow-up instrument. Diagnosis depends on clinical evaluation, the duration of the problem and the distress it causes.

What is the FSFI cutoff score?

The most used cutoff for the total score is 26.55: values at or below it suggest difficulty in sexual function (Wiegel et al., 2005). For the desire domain, the proposed cutoff is 5.0 (Gerstenberger et al., 2010).

Can I use the FSFI as a libido scale?

Yes, the desire domain (questions 1 and 2) works as a brief measure of libido. To assess whether low desire is a clinical problem, the associated distress is usually assessed too, for example with the FSDS-R.

I had no sexual activity in the past 4 weeks. Is the result valid?

With caveats. Without sexual activity, several questions score 0 and the total drops even without a real difficulty. The calculator warns you when this happens; in that case, read the result with caution.

From what age can the FSFI be used?

It was developed and validated in adult women. This tool is intended for people aged 18 and over.

Are my answers saved?

No. The calculation runs on your own device, and no answer is sent or stored. If you want to keep it, use “Copy result” or “Save PDF”.

How often can I retake the questionnaire?

Since it covers the past 4 weeks, it makes sense to repeat it at least 4 weeks apart — for example, to follow up after a change guided by a health professional.

References

  1. Rosen R, Brown C, Heiman J, et al. The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther. 2000;26(2):191-208. DOI 10.1080/009262300278597
  2. Wiegel M, Meston C, Rosen R. The Female Sexual Function Index (FSFI): cross-validation and development of clinical cutoff scores. J Sex Marital Ther. 2005;31(1):1-20. DOI 10.1080/00926230590475206
  3. Gerstenberger EP, Rosen RC, Brewer JV, et al. Sexual desire and the Female Sexual Function Index (FSFI): a sexual desire cutpoint for clinical interpretation of the FSFI in women with and without hypoactive sexual desire disorder. J Sex Med. 2010;7(9):3096-3103. DOI 10.1111/j.1743-6109.2010.01871.x
  4. Meston CM. Validation of the Female Sexual Function Index (FSFI) in women with female orgasmic disorder and in women with hypoactive sexual desire disorder. J Sex Marital Ther. 2003;29(1):39-46. DOI 10.1080/713847100
  5. Meston CM, Freihart BK, Handy AB, et al. Scoring and interpretation of the FSFI: what can be learned from 20 years of use? J Sex Med. 2020;17(1):17-25. DOI 10.1016/j.jsxm.2019.10.007
  6. Pacagnella RC, Vieira EM, Rodrigues OM Jr, Souza C. Adaptação transcultural do Female Sexual Function Index. Cad Saúde Pública. 2008;24(2):416-426. DOI 10.1590/S0102-311X2008000200021
  7. Pacagnella RC, Martinez EZ, Vieira EM. Validade de construto de uma versão em português do Female Sexual Function Index. Cad Saúde Pública. 2009;25(11):2333-2344. DOI 10.1590/S0102-311X2009001100004
  8. Isidori AM, Pozza C, Esposito K, et al. Development and validation of a 6-item version of the Female Sexual Function Index (FSFI) as a diagnostic tool for female sexual dysfunction. J Sex Med. 2010;7(3):1139-1146. DOI 10.1111/j.1743-6109.2009.01635.x
  9. Derogatis L, Clayton A, Lewis-D'Agostino D, et al. Validation of the Female Sexual Distress Scale-Revised for assessing distress in women with hypoactive sexual desire disorder. J Sex Med. 2008;5(2):357-364. DOI 10.1111/j.1743-6109.2007.00672.x
  10. Clayton AH, Goldstein I, Kim NN, et al. The International Society for the Study of Women's Sexual Health process of care for management of hypoactive sexual desire disorder in women. Mayo Clin Proc. 2018;93(4):467-487. DOI 10.1016/j.mayocp.2017.11.002
  11. Davis SR, Baber R, Panay N, et al. Global consensus position statement on the use of testosterone therapy for women. J Clin Endocrinol Metab. 2019;104(10):4660-4666. DOI 10.1210/jc.2019-01603
  12. Shifren JL, Monz BU, Russo PA, et al. Sexual problems and distress in United States women: prevalence and correlates. Obstet Gynecol. 2008;112(5):970-978. DOI 10.1097/AOG.0b013e3181898cdb

Important: This content is strictly educational and must not, under any circumstances, be used for self-diagnosis or treatment. It does not replace a consultation with a qualified health professional. Responsibility for the use of the information presented here lies entirely with the user.

I declare, transparently, that I have no conflict of interest with any pharmaceutical companies that may be mentioned. When I cite brand names or patented products, I do so solely to make the content easier to understand for the general public and to make medical knowledge more accessible.

All content on my website and social media aims to inform, educate and clarify — always free of charge.

No information shared here should be used as the sole criterion for evaluation, diagnosis or treatment decisions without proper professional guidance. Each person is unique and must be evaluated individually. Inappropriate use of this information, without medical follow-up, may pose serious health risks.

Content reviewed on November 18, 2026 by Dr. Diegomaier Nunes Neri — CRM/SC 32925 · CRM/BA 39586 (Brazil)